CLINICAL TRIALS PROFILE FOR NONOXYNOL-9
✉ Email this page to a colleague
All Clinical Trials for NONOXYNOL-9
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000926 ↗ | A Study of Nonoxynol-9 (N-9) and HIV Infection | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 1969-12-31 | The purpose of this study is to see if nonoxynol-9 (N-9) gel used in the vagina can prevent the spread of HIV. Most of the people with HIV in the world today live in southern Africa. Because this population is not likely to use condoms, an HIV-prevention method that women can control is needed. N-9 used in the vagina may help prevent the spread of HIV and other sexually transmitted diseases. |
| NCT00000929 ↗ | A Study of the Effects of Advantage 24 on the Rectum | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 1969-12-31 | The purpose of this study is to see if it is safe and acceptable for homosexual male couples, where both partners have the same HIV status, to use Advantage 24 during anal intercourse. Advantage 24 is a spermicide (a chemical that kills sperm). Much research and development is being done with chemicals that can be controlled by the receptive partner to prevent the spread of HIV and other sexually transmitted diseases (STDs). Advantage 24 currently is used in the vagina as a form of birth control. The safety of Advantage 24 is particularly important for HIV-positive men because they have a greater chance of serious reaction to Advantage 24 due to other HIV-related conditions. |
| NCT00016536 ↗ | Effects of BufferGel and PRO 2000/5 Gel in Men | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 1969-12-31 | The purpose of this study is to find out if there are any bad effects when BufferGel or PRO 2000/5 Gel are applied to the penis of HIV-infected men. Microbicides are products to be used by women for placing into the vagina to prevent passing HIV from 1 person to another during sex. Studies have shown 2 investigational microbicides, BufferGel and PRO 2000/5 Gel, to be safe and acceptable for women and HIV-negative men. It is important to see if the side effects of these products are the same in men as those in women and to see if there is any difference in the side effects between circumcised and uncircumcised men. |
| NCT00262106 ↗ | Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection | Completed | Department for International Development, United Kingdom | Phase 3 | 2005-10-01 | The objective of the study is to determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels compared to placebo in preventing vaginally acquired HIV infection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NONOXYNOL-9
Condition Name
Clinical Trial Locations for NONOXYNOL-9
Trials by Country
Clinical Trial Progress for NONOXYNOL-9
Clinical Trial Phase
Clinical Trial Sponsors for NONOXYNOL-9
Sponsor Name
